Skip to main content

Table 1 Baseline clinical characteristics of subjects who have an sRAGE measurement by cohort

From: Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD

  COPDGene (n = 1443) ECLIPSE (n = 2349) SCCOR (n = 399) SPIROMICS (n = 1623) p-value
Age (mean ± SD) 61 ± 9 62 ± 8 65 ± 6 64 ± 9 < 0.001
Sex (male) (%) 49% 62% 53% 54% < 0.001
Race (%)
 Non-Hispanic White 86% 93.5% 95% 75% < 0.001
 Non-Hispanic African American 14% 1.5% 4% 16%
 Other 0% 5% 1% 9%
BMI (kg/m2) (mean ± SD) 29 ± 6 27 ± 5 28 ± 4 28 ± 5 < 0.001
Never Smoker (%) 2% 9% 0% 8% < 0.001
Current Smoker (%) 39% 35% 42% 34%
Pack-years median (5th and 95th percentile) 38.4 (11.3; 90.0) 39 (0; 95) 46.0 (19.0; 118.0) 42.0 (0; 96.0) < 0.001
COPD (%) 41% 78% 48% 62% < 0.001
PRISm (%) 10% 0.2% 5% 2% < 0.001
FEV1 (% predicted) (mean ± SD) 81 ± 25 62 ± 30 83 ± 20 76 ± 26 < 0.001
FEV1 (L) (mean ± SD) 2.36 ± 0.91 1.79 ± 1.00 2.39 ± 0.76 2.15 ± 0.91 < 0.001
FVC (L) (mean ± SD) 3.44 ± 1.00 3.30 ± 1.03 3.54 ± 0.89 3.44 ± 1.02 0.006
Emphysema (% LAA < − 950 HU) median (5th and 95th percentile) 1.40 (0.08; 26.19) 11.48 (0.49; 39.18) 0.80 (0.10; 17.40) 3.07 (0.29; 29.54) < 0.001
PD15adj (g/L) (mean ± SD) 89 ± 24 61 ± 26 87 ± 21 83 ± 26 < 0.001
History of diabetes (%) 11% 9% 8% 13% < 0.001
History of heart attack (%) 6% 8% 5% 6% 0.009
History of coronary artery disease (%) 7% NC 6% 9% 0.12
History of stroke (%) 2% 3% 3% 4% 0.11
Follow-up (years) median (5th and 95th percentile) 5.14 (0; 10.1) 3.0 (1.5; 3.0) 6.0 (2.0; 6.0) 3.1 (0; 7.5) < 0.001
Percentage of visits with a spirometry per participant
 0 0.1%    0.1%  
 1 39% 0.04%   12%  
 2 44% 0.04% 39% 12%  
 3 16% 1% 61% 18%  
 4   4%   34%  
 5   4%   24%  
 6   5%    
 7   10%    
 8   76%    
Number of visits with CT scan per participant
 0 1% 7%   0.1%  
 1 41% 11%   13%  
 2 58% 21% 39% 50%  
 3   61% 61% 36%  
  1. To evaluate differences between cohorts, analysis of variance (ANOVA) was used for normally distributed continuous variables and Kruskal–Wallis test for non-normaly distributed variables; and a Chi square/Fisher’s exact test for categorical
  2. COPD chronic obstructive pulmonary disease, PRISm Preserved Ratio Impaired Spirometry, FEV1 forced expiratory volume in one second, FVC forced vital capacity, PD15adj HU of the 15th Percentile adjusted for total lung capacity, NC not collected